Loading patent…
AssigneeYonggang XIA
InventorsYonggang XIA, Jun LIANG
Estimating the term…
A use of Auricularia auricula total polysaccharide or monomeric polysaccharide in preparation of a PD-L1 inhibitor is provided. The Auricularia auricula total polysaccharide or monomeric polysaccharide both contain acetyl active groups. The Auricularia auricula total polysaccharide or monomeric polysaccharide containing acetyl active groups can effectively inhibit the expression of PD-L1 protein in tumor cells, inhibit the proliferation of tumor cells, and can be used as a natural PD-L1 inhibitor for the treatment of various tumors with high expression of PD-L1, such as lung cancer and colon cancer. Compared with the existing PD-L1 inhibitors, the use of Auricularia auricula total polysaccharide or monomeric polysaccharide as a PD-L1 inhibitor has the advantages of non-toxic side effects, low price, and wide adaptation to patient groups.
A preparation method of a programmed cell death ligand 1 (PD-L1) inhibitor, comprising using an Auricularia auricula total polysaccharide, wherein a content of acetyl active groups in the Auricularia auricula total polysaccharide is more than 10%.
A preparation method of a PD-L1 inhibitor, comprising using a monomeric polysaccharide isolated from Auricularia auricula, wherein a content of acetyl active groups of the monomeric polysaccharide is 18.0%.
A pharmaceutical composition for inhibiting PD-L1 or treating a tumor, comprising an effective amount of an Auricularia auricula total polysaccharide or an Auricularia auricula monomeric polysaccharide and an acceptable excipient or carrier in a pharmaceutical preparation;
Dependencies are inferred from the claim text.